Science-Based Medicine13m
Your Brain In Space
Amid all the shocking and depressing news regarding the future of American healthcare and medicine, at least over the next ...
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...
Promising results from phase 1 gene therapy trial for Danon disease
Researchers at Children's Hospital of Philadelphia (CHOP) announced encouraging results from the first ever gene therapy ...
BioSpace20h
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
PsyPost on MSN3d
Surprising ADHD research finds greater life demands linked to reduced symptoms
The research, published in the Journal of Clinical Psychiatry, suggests that ADHD is not a simple condition that either ...
Promising Clinical Developments and Data Catalysts Position Affimed for Strong Future Prospects
Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Affimed (AFMD – Research Report), retaining the price target ...
Unlocking future medicines: The crucial role of clinical trials
Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...
SF Weekly6d
Leen Kawas Details the Factors Behind High Drug Development Costs (and Presents Strategies to Address Them)
Phase 1: Discovery and Preclinical Phases: Identification and testing of potential drug compounds. Duration: 1 to 6 years.
rmdopen.bmj7d
Is rheumatoid arthritis always preceded by a symptomatic at-risk phase of arthralgia?
Objectives Secondary prevention of rheumatoid arthritis (RA) is generally considered potentially impactful because the entire ...
Business Wire7d
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter ...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...